Clinical Factors to Predict the Response to Concurrent Chemoradiotherapy and Survival in Esophageal Cancer Patients

Overview

Journal Gut Liver

Specialty Gastroenterology

Date 2020 Feb 1

PMID 32000467

Citations 6

Authors

Su Youn Nam

Seong Woo Jeon

Sang Jik Lee

Yong Hwan Kwon

Hyun Seok Lee

Sung Kook Kim

Affiliations

Soon will be listed here.

Abstract

Background/aims: Several clinical factors have been used to predict the response for concurrent chemoradiotherapy (CCRT); however, these factors are insufficient for prognostic predictions. We investigated clinical factors to assess whether they could be used to predict the response to CCRT and the survival of patients with esophageal cancer.

Methods: Patients with esophageal cancer underwent CCRT from January 2005 to December 2015. Response to CCRT was classified as progressive disease (PD), stationary disease (SD), partial remission (PR), or complete remission (CR). Factors to predict the response to CCRT and patient survival were subsequently investigated.

Results: A total of 535 esophageal cancer patients underwent CCRT. Four hundred ninety-three patients were followed up, and patient outcomes were investigated. In the adjusted analysis, patients with advanced stage disease (relative risk [RR], 0.28 in stage III and 0.12 in stage IV compared to stage I), poor performance status, circumferential involvement (RR, 0.61), and male sex (RR, 0.31) were less likely to achieve CR. Advanced stage disease (hazard ratio [HR], 1.71 in stage III/IV), poor CCRT response (HR, 2.82 in PR, 4.47 in SD, 4.77 in PD compared to CR), and poor performance status (HR, 1.38 in ECOG 2-4) were found to increase mortality.

Conclusions: Advanced stage disease, poor performance status, male sex, and circumferential involvement were independent predictive factors for a poor response to CCRT. Advanced stage, poor performance status, and poor CCRT response were independent factors for decreased survival.

Citing Articles

Spectral CT-based nomogram for evaluation of neoadjuvant chemotherapy response in esophageal squamous cell carcinoma.

Wang J, Zhu Y, Li Q, Wang L, Bian H, Lu X Eur Radiol. 2024; .

PMID: 39729110 DOI: 10.1007/s00330-024-11294-2.

Nomogram for predicting pathologic complete response following preoperative chemoradiotherapy in patients with esophageal squamous cell carcinoma.

Shin Y, Jang J, Yoo Y, Yu J, Song K, Jo Y Gastroenterol Rep (Oxf). 2024; 12:goae060.

PMID: 38974878 PMC: 11227365. DOI: 10.1093/gastro/goae060.

The relationship between the treatment course and prognosis of oligometastasis after esophageal squamous cell carcinoma resection.

Matsumoto C, Iwatsuki M, Morinaga T, Horinouchi T, Hara Y, Baba Y Surg Today. 2024; 54(8):927-934.

PMID: 38583108 DOI: 10.1007/s00595-024-02803-3.

Clinicopathological characteristics and treatment outcomes of oesophageal cancer patients in Uganda.

Obayo S, Mulumba Y, Thompson C, Gibson M, Cooney M, Orem J Ecancermedicalscience. 2023; 17:1576.

PMID: 37533943 PMC: 10393309. DOI: 10.3332/ecancer.2023.1576.

Elevated Platelet-to-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio after First Cycle of Chemotherapy and Better Survival in Esophageal Cancer Patients Receiving Concurrent Chemoradiotherapy.

Tseng R, Lai K, Tsai C, Yan S Curr Oncol. 2022; 29(11):8825-8834.

PMID: 36421347 PMC: 9689285. DOI: 10.3390/curroncol29110694.

References

Gao Y, Zhu J, Zhang X, Wu Q, Jiang S, Liu Y . BRCA1 mRNA expression as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma treated with cisplatin- or docetaxel-based chemotherapy/chemoradiotherapy. PLoS One. 2013; 8(1):e52589. PMC: 3541365. DOI: 10.1371/journal.pone.0052589. View

Pickens A, Orringer M . Geographical distribution and racial disparity in esophageal cancer. Ann Thorac Surg. 2003; 76(4):S1367-9. DOI: 10.1016/s0003-4975(03)01202-5. View

Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T . Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007; 25(10):1160-8. DOI: 10.1200/JCO.2005.04.7118. View

Zhu L, Yuan L, Wang H, Ye L, Yao G, Liu C . A Meta-Analysis of Concurrent Chemoradiotherapy for Advanced Esophageal Cancer. PLoS One. 2015; 10(6):e0128616. PMC: 4457836. DOI: 10.1371/journal.pone.0128616. View

Duong C, Greenawalt D, Kowalczyk A, Ciavarella M, Raskutti G, Murray W . Pretreatment gene expression profiles can be used to predict response to neoadjuvant chemoradiotherapy in esophageal cancer. Ann Surg Oncol. 2007; 14(12):3602-9. DOI: 10.1245/s10434-007-9550-1. View

Skinner H, Lee J, Bhutani M, Weston B, Hofstetter W, Komaki R . A validated miRNA profile predicts response to therapy in esophageal adenocarcinoma. Cancer. 2014; 120(23):3635-41. PMC: 4239178. DOI: 10.1002/cncr.28911. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2016. CA Cancer J Clin. 2016; 66(1):7-30. DOI: 10.3322/caac.21332. View

Al-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle J, VAITKEVICIUS V . Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol. 1997; 15(1):277-84. DOI: 10.1200/JCO.1997.15.1.277. View

Ajani J, Wang X, Song S, Suzuki A, Taketa T, Sudo K . ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients. Mol Oncol. 2013; 8(1):142-9. PMC: 3946849. DOI: 10.1016/j.molonc.2013.10.007. View

10.

Wen J, Yang H, Liu M, Luo K, Liu H, Hu Y . Gene expression analysis of pretreatment biopsies predicts the pathological response of esophageal squamous cell carcinomas to neo-chemoradiotherapy. Ann Oncol. 2014; 25(9):1769-1774. DOI: 10.1093/annonc/mdu201. View

11.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

12.

Kimura J, Kunisaki C, Makino H, Oshima T, Ota M, Oba M . Evaluation of the Glasgow Prognostic Score in patients receiving chemoradiotherapy for stage III and IV esophageal cancer. Dis Esophagus. 2015; 29(8):1071-1080. DOI: 10.1111/dote.12420. View

13.

Chao Y, Tseng C, Wen Y, Liu Y, Wan Y, Chiu C . Using pretreatment tumor depth and length to select esophageal squamous cell carcinoma patients for nonoperative treatment after neoadjuvant chemoradiotherapy. Ann Surg Oncol. 2013; 20(9):3000-8. DOI: 10.1245/s10434-013-2962-1. View

14.

Ishida K, Ando N, Yamamoto S, Ide H, Shinoda M . Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol. 2004; 34(10):615-9. DOI: 10.1093/jjco/hyh107. View

15.

Amini A, Ajani J, Komaki R, Allen P, Minsky B, Blum M . Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. Ann Surg Oncol. 2013; 21(1):306-14. DOI: 10.1245/s10434-013-3303-0. View

16.

Izzo J, Malhotra U, Wu T, Ensor J, Luthra R, Lee J . Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol. 2006; 24(5):748-54. DOI: 10.1200/JCO.2005.03.8810. View

17.

Brabender J, Vallbohmer D, Grimminger P, Hoffmann A, Ling F, Lurje G . ERCC1 RNA expression in peripheral blood predicts minor histopathological response to neoadjuvant radio-chemotherapy in patients with locally advanced cancer of the esophagus. J Gastrointest Surg. 2008; 12(11):1815-21. DOI: 10.1007/s11605-008-0668-7. View

18.

Nomura M, Shitara K, Kodaira T, Kondoh C, Takahari D, Ura T . Recursive partitioning analysis for new classification of patients with esophageal cancer treated by chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2012; 84(3):786-92. DOI: 10.1016/j.ijrobp.2011.12.069. View

19.

Di Fiore F, Lecleire S, Rigal O, Galais M, Ben Soussan E, David I . Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma. World J Gastroenterol. 2006; 12(26):4185-90. PMC: 4087370. DOI: 10.3748/wjg.v12.i26.4185. View

20.

Kato K, Muro K, Minashi K, Ohtsu A, Ishikura S, Boku N . Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 2010; 81(3):684-90. DOI: 10.1016/j.ijrobp.2010.06.033. View